Form 4: Akero COO Young Exercises Options, Gifts Shares

Akero Therapeutics' Chief Operating Officer, Jonathan Young, reported exercising stock options and gifting a portion of his common stock holdings.

Summary

• Jonathan Young, Chief Operating Officer of Akero Therapeutics, Inc., reported multiple transactions involving the company's common stock.
• On November 24, 2025, Young exercised stock options to acquire a total of 12,550 shares of common stock.
• These acquisitions included 4,284 shares at an exercise price of $21.09, 3,527 shares at $28.35, and 4,739 shares at $21.10.
• Following these exercises, Young's direct beneficial ownership increased to 209,448 shares.
• On November 26, 2025, Young disposed of 9,259 shares of common stock as a gift to a donor-advised fund, with a transaction price of $0.
• After the gift, Young's direct beneficial ownership stands at 200,189 shares.
• Young also indirectly holds 60,000 shares across three irrevocable trusts (EA, CM, and JL Irrevocable Trusts) for the benefit of his children, though he disclaims beneficial ownership of these securities.

Sentiment

Score: 6

Explanation: The exercise of options indicates a positive action by the COO to convert equity awards into shares, which can be seen as a sign of confidence. However, the subsequent gift of shares slightly offsets this, making the overall sentiment neutral to slightly positive as it's a routine personal financial management event rather than a direct investment decision.

Positives

• The exercise of stock options indicates a decision by the Chief Operating Officer to convert equity awards into common stock, which can be interpreted as a sign of confidence in the company's future.
• The options exercised were vested and currently exercisable, reflecting a mature equity compensation plan for the executive.

Negatives

• The disposition of 9,259 shares as a gift reduces the direct beneficial ownership of the Chief Operating Officer.

Future Outlook

NA

Industry Context

This filing is a routine insider transaction report and does not provide specific industry context. It reflects an individual executive's equity management decisions within the biotechnology sector, which are common for executives with stock-based compensation.

Related Party Transactions

• Jonathan Young indirectly holds 20,000 shares each in the EA Irrevocable Trust, CM Irrevocable Trust, and JL Irrevocable Trust, established for the benefit of his children. His spouse is the trustee of these trusts. Young disclaims beneficial ownership of these securities.

Stakeholder Impact

• Shareholders: The transactions represent routine insider activity, providing transparency into executive stock ownership changes. The net effect on total outstanding shares is negligible from these transactions alone.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions (option exercises and a gift of shares) by the Chief Operating Officer. While option exercises can sometimes signal management confidence, the subsequent gift of shares is a personal financial decision and not indicative of a significant change in the company's fundamental outlook or performance. These transactions are generally not considered price-sensitive and do not provide a basis for a 'buy' or 'sell' recommendation. Investors should 'hold' and look to more substantive filings (e.g., 10-K, 10-Q) for investment decisions.

Keywords

Akero Therapeutics, AKRO, Jonathan Young, COO, Stock Option Exercise, Insider Transaction, Form 4, Equity Compensation, Share Disposition, Gift